BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).

This study is ongoing, but not recruiting participants.

Sponsor:

Collaborator:

Eli Lilly and Company

Information provided by (Responsible Party):

Boehringer Ingelheim

ClinicalTrials.gov Identifier:

NCT01131676

First received: May 26, 2010

Last updated: February 20, 2015

Last verified: February 2015

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study is ongoing, but not recruiting participants.
Estimated Study Completion Date:	April 2015
Estimated Primary Completion Date:	April 2015 (Final data collection date for primary outcome measure)

No publications provided by Boehringer Ingelheim

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):